Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy
|ClinicalTrials.gov Identifier: NCT00076206|
Recruitment Status : Terminated
First Posted : January 19, 2004
Last Update Posted : December 9, 2015
|Condition or disease||Intervention/treatment||Phase|
|Rheumatoid Arthritis||Drug: CCI-779 Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Oral Dose Levels (1, 2, And 4 Mg) of CCI-779 in Subjects With Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy|
|Study Start Date :||December 2003|
|Primary Completion Date :||August 2005|
|Study Completion Date :||August 2005|
CCI-779 1 mg dose to be taken orally daily up to 12 weeks.
CCI-779 2 mg dose to be taken orally daily up to 12 weeks.
CCI-779 4 mg dose to be taken orally daily up to 12 weeks.
Placebo Comparator: D
Placebo dose to be taken orally daily up to 12 weeks.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00076206
|Study Director:||Medical Monitor, MD||Wyeth is now a wholly owned subsidiary of Pfizer|